Last reviewed · How we verify
RTX treatment
RTX is a robotic stereotactic radiosurgery system that delivers highly focused radiation beams to target intracranial lesions with sub-millimeter precision.
RTX is a robotic stereotactic radiosurgery system that delivers highly focused radiation beams to target intracranial lesions with sub-millimeter precision. Used for Intracranial tumors (primary and metastatic), Arteriovenous malformations, Functional neurosurgical applications.
At a glance
| Generic name | RTX treatment |
|---|---|
| Sponsor | Xuanwu Hospital, Beijing |
| Modality | Small molecule |
| Therapeutic area | Oncology, Neurosurgery |
| Phase | FDA-approved |
Mechanism of action
RTX uses robotic-guided radiation delivery to concentrate high doses of ionizing radiation on tumors, vascular malformations, or functional targets while minimizing exposure to surrounding healthy brain tissue. The system employs real-time imaging and automated positioning to achieve precise targeting, making it suitable for both ablative and functional neurosurgical applications.
Approved indications
- Intracranial tumors (primary and metastatic)
- Arteriovenous malformations
- Functional neurosurgical applications
Common side effects
- Headache
- Transient edema
- Radiation necrosis (delayed)
Key clinical trials
- Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain (PHASE1, PHASE2)
- Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer (PHASE1)
- Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD
- Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis (PHASE3)
- Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee (PHASE3)
- Actinium Therapy for Late-stage Aggressive Sarcomas (PHASE1)
- Efficacy and Safety of Different Doses of Rituximab Therapy in Pemphigus Patients
- Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RTX treatment CI brief — competitive landscape report
- RTX treatment updates RSS · CI watch RSS
- Xuanwu Hospital, Beijing portfolio CI